Australia-listed stem cell biotech Mesoblast prices IPO at $8, below expectations
11/13/15
Column 1 0 Mesoblast, which is developing regenerative medicine based on adult stem cells, raised $60 million by offering 7.5 million ADSs at $8, well below the expected $12.10 price. Mesoblast plans to list on the Nasdaq under the symbol MESO. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
Australia-listed stem cell biotech Mesoblast prices IPO at $8, below expectations
11/13/15
http://www.nasdaq.com/article/austr...t-prices-ipo-at-8-below-expectations-cm542749
http://www.renaissancecapital.com/n...ast-prices-ipo-at-$8-below-expecta-37237.html
MSO IPO 13 Nov, 2015, page-2
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |